
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is a comprehensive provider of cancer diagnostic testing, with a strong position in the community channel and a wide range of tests offered. We believe that the company's base clinical services business will continue to deliver steady MSD% growth, driven by an increasing contribution from the faster growth NGS segment and potential upside from new test launches. Additionally, management's efforts to optimize and increase ASP, as well as expansion into flow cytometry for heme MRD, could drive margin and cash flow improvement. With a strong foothold in the market, favorable outlook for NGS growth, and attractive positioning trading at <2x EV/S, we have a positive outlook on NeoGenomics.
Bears say
NeoGenomics is currently facing challenges in terms of environmental, social, and corporate governance (ESG) performance, as the company's focus on providing oncology diagnostic testing and services may not align with changing regulations and trends in healthcare. Additionally, the company's materiality assessment process may need to be revised in order to accurately capture and respond to important ESG factors. These challenges, combined with the company's overly conservative revenue projections and expected decline in non-clinical revenue, contribute to a negative outlook on NeoGenomics's stock.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares